ERT Delivers Actionable Insights to Identify COVID-related Clinical Trial Risks

ERT Delivers Actionable Insights to Identify COVID-related Clinical Trial Risks

 Intuitive COVID-19 Dashboard highlights patient compliance risks to protect study outcomes

PHILADELPHIA – April 20, 2020 – ERT, a global data and technology company that captures critical endpoint data while minimizing uncertainty and risk in clinical trials, today announced new reporting capabilities that help clinical trial sponsors and CROs ensure high-quality data collection during current global stay-home mandates. The newly launched COVID-19 Dashboard integrates data on coronavirus infection rates in geographic areas surrounding study investigative sites, so sponsors can identify and proactively intervene where patient and site compliance to study protocols may be at risk.

In order to get high-quality data that demonstrates their compound’s efficacy and safety, sponsors need to ensure patients are completing self-reported assessments as directed by the study protocol. When patient compliance drops, data quality suffers, which puts clinical development programs at risk. Because of current pandemic-related restrictions limiting in-person patient access to investigative sites, the risk of patient non-compliance increases. To mitigate this risk, clinical trial sponsors need robust, easy-to-access tools to identify protocol compliance risks before they cause data quality problems.

ERT’s COVID-19 Dashboard helps sponsors identify areas of imminent risk caused by reduced patient site visits, enabling them to intervene and keep patients engaged throughout clinical trials. The dashboard presents convenient views of COVID-19 cases in relation to study site locations, flags sites and patients with potential device/data risks, and enables a targeted intervention approach toward real-time study monitoring to ensure data quality, regardless of patient access to investigative sites.

“With the COVID-19 Dashboard, sponsors don’t have to waste time searching multiple sources to identify data collection, correction, and transmission issues that could negatively impact data quality,” said Otis Johnson, Ph.D., Vice President of Trial Oversight at ERT. “Our proprietary cloud-based data management and analytics platform enables us to quickly deliver actionable insights and put important information at our customers’ fingertips so they can easily identify problem areas and take action to maintain the integrity of their studies.”

Click here to learn more about ERT’s COVID Dashboard and other Business Intelligence tools.

###

About ERT
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards.

Powered by the company’s EXPERT^® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. In 2019, 75% of all FDA drug approvals came from ERT-supported studies. Pharma companies, biotechs, and CROs have relied on ERT solutions across 15,000 studies, spanning more than four million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly ─ and with confidence.

For more information, go to ert.com or follow us on LinkedIn and Twitter